Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression

Fig. 1

Disease-monitoring algorithm. aQuestionnaire to be performed prior to consultation. bAdditional test. 6MWT 6-min walk test, ACV abnormal conjunctival vessel, cMRI cardiac magnetic resonance imaging, COMPASS-31 Composite Autonomic Symptom Score-31, DPD 99mTc-3,3-diphosphono-1,2-propanodicarboxylicacid, ECG electrocardiogram, eGFR estimated glomerular filtration rate, HRDB heart rate deep breathing, KCCQ Kansas City Cardiac Questionnaire, KCS keratoconjunctivitis sicca, mBMI modified body mass index, NCS nerve conduction study, Norfolk QOL-DN Norfolk Quality of Life-Diabetic Neuropathy, NT-proBNP N-terminal prohormone of brain-type natriuretic peptide, OH orthostatic hypotension, OLT orthotopic liver transplantation, PND polyneuropathy disability, PYP 99mTc-pyrophosphate, QOL quality of life, R-ODS Rasch-built Overall Disability Scale, SF-36 36-item Short-Form Healthy Survey, SFN-SIQ small-fiber neuropathy and symptom inventory questionnaire

Back to article page